港股異動 | 再鼎醫藥(9688.HK)首日上市高開9.16%
格隆匯9月28日丨再鼎醫藥(9688.HK)首日上市開報613.5港元,較發行價562港元漲9.16%,暫成交1.6億港元,最新總市值527億港元。公司為一間創新型、立足研發及處於商業階段的生物製藥公司,2018年、2019年收益分別為12.9萬、1298.5萬美元,普通股股東應占虧損1.39億、1.95億美元,每股有形資產淨值119.5港元。據悉,公司已於2017年9月在美國納斯達克上市,本次在香港二次上市擬全球發售1056.405萬股,其中香港發售89.8萬股,國際發售966.605萬股,每手50股,香港公開發售獲3.43倍認購;淨籌約57.304億港元,當中46.2%將分配至核心產品的研發工作。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.